Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss.

Sapir-Pichhadze R, Zhang X, Ferradji A, Madbouly A, Tinckam KJ, Gebel HM, Blum D, Marrari M, Kim SJ, Fingerson S, Bashyal P, Cardinal H, Foster BJ.

Kidney Int. 2019 Nov 12. pii: S0085-2538(19)31132-9. doi: 10.1016/j.kint.2019.10.028. [Epub ahead of print]

PMID:
32059998
2.

Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin.

Blum D, Beaubien-Souligny W, Battistella M, Tseng E, Harel Z, Nijjar J, Nazvitch E, Silver SA, Wald R.

Kidney Int Rep. 2019 Nov 6;5(2):159-164. doi: 10.1016/j.ekir.2019.10.011. eCollection 2020 Feb.

3.

Impact, challenges and limits of inpatient palliative care consultations - perspectives of requesting and conducting physicians.

Coym A, Oechsle K, Kanitz A, Puls N, Blum D, Bokemeyer C, Ullrich A.

BMC Health Serv Res. 2020 Feb 4;20(1):86. doi: 10.1186/s12913-020-4936-x.

4.

Necrotizing Fasciitis: Pillaging the Acute Phase Response.

Hysong AA, Posey SL, Blum DM, Benvenuti MA, Benvenuti TA, Johnson SR, An TJ, Devin JK, Obremskey WT, Martus JE, Moore-Lotridge SN, Schoenecker JG.

J Bone Joint Surg Am. 2020 Jan 22. doi: 10.2106/JBJS.19.00591. [Epub ahead of print] No abstract available.

PMID:
31977818
5.

Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology.

Sierksma A, Lu A, Mancuso R, Fattorelli N, Thrupp N, Salta E, Zoco J, Blum D, Buée L, De Strooper B, Fiers M.

EMBO Mol Med. 2020 Jan 17:e10606. doi: 10.15252/emmm.201910606. [Epub ahead of print]

6.

Predicting mortality among critically ill patients with acute kidney injury treated with renal replacement therapy: Development and validation of new prediction models.

Li DH, Wald R, Blum D, McArthur E, James MT, Burns KEA, Friedrich JO, Adhikari NKJ, Nash DM, Lebovic G, Harvey AK, Dixon SN, Silver SA, Bagshaw SM, Beaubien-Souligny W.

J Crit Care. 2019 Dec 18;56:113-119. doi: 10.1016/j.jcrc.2019.12.015. [Epub ahead of print]

PMID:
31896444
7.

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate.

Rogin J, Resnick T, Strom L, Ben-Menachem E, Kochen S, Blum D, Gama H, Soares-da-Silva P, Li Y, Grinnell T.

Acta Neurol Scand. 2020 Jan 1. doi: 10.1111/ane.13218. [Epub ahead of print]

PMID:
31894578
8.

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures.

Mintz M, Pina-Garza JE, Wolf SM, McGoldrick PE, Józwiak S, Grinnell T, Cantu D, Costa R, Moreira J, Li Y, Blum D.

J Child Neurol. 2020 Mar;35(4):265-273. doi: 10.1177/0883073819890997. Epub 2019 Dec 26.

PMID:
31878820
9.

Mobile Health Technologies for Continuous Monitoring of Cancer Patients in Palliative Care Aiming to Predict Health Status Deterioration: A Feasibility Study.

Pavic M, Klaas V, Theile G, Kraft J, Tröster G, Blum D, Guckenberger M.

J Palliat Med. 2019 Dec 23. doi: 10.1089/jpm.2019.0342. [Epub ahead of print]

PMID:
31873052
10.

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, Pahwa R, Leinonen M, Bhargava P, Sciarappa K, Navia B, Blum D; CTH-300 Study investigators.

Lancet Neurol. 2020 Feb;19(2):135-144. doi: 10.1016/S1474-4422(19)30396-5. Epub 2019 Dec 7.

PMID:
31818699
11.

Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models.

Faldini E, Ahmed T, Bueé L, Blum D, Balschun D.

Acta Neuropathol Commun. 2019 Dec 9;7(1):202. doi: 10.1186/s40478-019-0813-4.

12.

NLRP3 inflammasome activation drives tau pathology.

Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, Griep A, Santarelli F, Brosseron F, Opitz S, Stunden J, Merten M, Kayed R, Golenbock DT, Blum D, Latz E, Buée L, Heneka MT.

Nature. 2019 Nov;575(7784):669-673. doi: 10.1038/s41586-019-1769-z. Epub 2019 Nov 20.

PMID:
31748742
13.

The Frequency of Routine Blood Sampling and Patient Outcomes Among Maintenance Hemodialysis Recipients.

Thomas A, Silver SA, Perl J, Freeman M, Slater JJ, Nash DM, Vinegar M, McArthur E, Garg AX, Harel Z, Chanchlani R, Zappitelli M, Iliescu E, Kitchlu A, Blum D, Beaubien-Souligny W, Wald R.

Am J Kidney Dis. 2019 Nov 12. pii: S0272-6386(19)31007-8. doi: 10.1053/j.ajkd.2019.08.016. [Epub ahead of print]

PMID:
31732233
14.

Predisposing and precipitating risk factors for delirium in palliative care patients.

Seiler A, Schubert M, Hertler C, Schettle M, Blum D, Guckenberger M, Weller M, Ernst J, von Känel R, Boettger S.

Palliat Support Care. 2019 Nov 14:1-10. doi: 10.1017/S1478951519000919. [Epub ahead of print]

PMID:
31722766
15.

Meta-Analysis of Randomized Controlled Trials Using Tool-Assisted Target Weight Adjustments in Chronic Dialysis Patients.

Beaubien-Souligny W, Kontar L, Blum D, Bouchard J, Denault AY, Wald R.

Kidney Int Rep. 2019 Jul 12;4(10):1426-1434. doi: 10.1016/j.ekir.2019.07.003. eCollection 2019 Oct.

16.

Caffeine Consumption During Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy.

Zappettini S, Faivre E, Ghestem A, Carrier S, Buée L, Blum D, Esclapez M, Bernard C.

Front Cell Neurosci. 2019 Oct 1;13:438. doi: 10.3389/fncel.2019.00438. eCollection 2019.

17.

Markers of bone and lipid metabolism with eslicarbazepine acetate monotherapy.

Mintzer S, Constantino T, Gidal B, Bhargava P, Grinnell T, Blum D.

Epilepsy Res. 2019 Dec;158:106216. doi: 10.1016/j.eplepsyres.2019.106216. Epub 2019 Oct 14.

18.

The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates.

Nebie O, Devos D, Vingtdeux V, Barro L, Devedjian JC, Jonneaux A, Chou ML, Bordet R, Buée L, Knutson F, Blum D, Burnouf T.

J Biomed Sci. 2019 Oct 31;26(1):89. doi: 10.1186/s12929-019-0579-9.

19.

The Storytelling Brain: How Neuroscience Stories Help Bridge the Gap between Research and Society.

Martinez-Conde S, Alexander RG, Blum D, Britton N, Lipska BK, Quirk GJ, Swiss JI, Willems RM, Macknik SL.

J Neurosci. 2019 Oct 16;39(42):8285-8290. doi: 10.1523/JNEUROSCI.1180-19.2019.

PMID:
31619498
20.

Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor.

Carvalho K, Faivre E, Pietrowski MJ, Marques X, Gomez-Murcia V, Deleau A, Huin V, Hansen JN, Kozlov S, Danis C, Temido-Ferreira M, Coelho JE, Mériaux C, Eddarkaoui S, Gras SL, Dumoulin M, Cellai L; NeuroCEB Brain Bank, Landrieu I, Chern Y, Hamdane M, Buée L, Boutillier AL, Levi S, Halle A, Lopes LV, Blum D.

Brain. 2019 Nov 1;142(11):3636-3654. doi: 10.1093/brain/awz288.

21.

Thinking Volume First: Developing a Multifaceted Systematic Approach to Volume Management in Hemodialysis.

Blum D, Beaubien-Souligny W, Silver SA, Wald R.

Can J Kidney Health Dis. 2019 Sep 26;6:2054358119879776. doi: 10.1177/2054358119879776. eCollection 2019.

22.

Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer's disease with FDG-PET.

Blum D, Liepelt-Scarfone I, Berg D, Gasser T, la Fougère C, Reimold M; Alzheimer’s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2370-2379. doi: 10.1007/s00259-019-04400-w. Epub 2019 Jul 24.

PMID:
31338550
23.

A2A R-induced transcriptional deregulation in astrocytes: An in vitro study.

Paiva I, Carvalho K, Santos P, Cellai L, Pavlou MAS, Jain G, Gnad T, Pfeifer A, Vieau D, Fischer A, Buée L, Outeiro TF, Blum D.

Glia. 2019 Dec;67(12):2329-2342. doi: 10.1002/glia.23688. Epub 2019 Jul 22.

PMID:
31328322
24.

Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.

Wechsler RT, Radtke RA, Smith M, Vossler DG, Strom L, Trinka E, Cheng H, Grinnell T, Blum D, Vieira M, Moreira J, Rocha F.

Epilepsia. 2019 Jul;60(7):1341-1352. doi: 10.1111/epi.16069. Epub 2019 Jul 1.

25.

The Size of Intramedullary Fixation Affects Endochondral-Mediated Angiogenesis During Fracture Repair.

Yuasa M, Saito M, Blum DM, Hysong AA, Egawa S, Uppuganti S, Yoshii T, Okawa A, Schwartz HS, Moore-Lotridge SN, Nyman JS, Schoenecker JG.

J Orthop Trauma. 2019 Oct;33(10):e385-e393. doi: 10.1097/BOT.0000000000001555.

PMID:
31259800
26.

Selective Collection of Particulate Ammonium for Nitrogen Isotopic Characterization Using a Denuder-Filter Pack Sampling Device.

Walters WW, Blum DE, Hastings MG.

Anal Chem. 2019 Jun 18;91(12):7586-7594. doi: 10.1021/acs.analchem.9b00151. Epub 2019 Jun 4.

PMID:
31117401
27.

Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.

Chung S, Sinha SR, Shah A, Stern JM, Cheng H, Jung J, Grinnell T, Blum D.

Epilepsy Res. 2019 Jul;153:59-65. doi: 10.1016/j.eplepsyres.2019.03.018. Epub 2019 Mar 29.

PMID:
30999260
28.

New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease.

Sergeant N, Vingtdeux V, Eddarkaoui S, Gay M, Evrard C, Le Fur N, Laurent C, Caillierez R, Obriot H, Larchanché PE, Farce A, Coevoet M, Carato P, Kouach M, Descat A, Dallemagne P, Buée-Scherrer V, Blum D, Hamdane M, Buée L, Melnyk P.

Neurobiol Dis. 2019 Sep;129:217-233. doi: 10.1016/j.nbd.2019.03.028. Epub 2019 Mar 27.

PMID:
30928644
29.

Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model.

Leboucher A, Ahmed T, Caron E, Tailleux A, Raison S, Joly-Amado A, Marciniak E, Carvalho K, Hamdane M, Bantubungi K, Lancel S, Eddarkaoui S, Caillierez R, Vallez E, Staels B, Vieau D, Balschun D, Buee L, Blum D.

Neurobiol Dis. 2019 May;125:14-22. doi: 10.1016/j.nbd.2019.01.008. Epub 2019 Jan 19.

PMID:
30665005
30.

Atypical parkinsonism with severely reduced striatal dopamine uptake associated with a 16p11.2 duplication syndrome.

Roeben B, Blum D, Gabriel H, Synofzik M.

J Neurol. 2019 Mar;266(3):775-776. doi: 10.1007/s00415-019-09182-7. Epub 2019 Jan 7. No abstract available.

PMID:
30617906
31.

Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials.

Cramer JA, Rajagopalan K, Anastassopoulos KP, Blum D; Covance.

Epilepsy Behav. 2019 Mar;92:31-35. doi: 10.1016/j.yebeh.2018.12.003. Epub 2019 Jan 2.

PMID:
30611005
32.

[Brain insulin signaling and Tau: impact for Alzheimer's disease and Tauopathies].

Joly-Amado A, Gratuze M, Benderradji H, Vieau D, Buée L, Blum D.

Med Sci (Paris). 2018 Nov;34(11):929-935. doi: 10.1051/medsci/2018238. Epub 2018 Dec 10. Review. French.

33.

Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology.

Sierksma A, Lu A, Salta E, Vanden Eynden E, Callaerts-Vegh Z, D'Hooge R, Blum D, Buée L, Fiers M, De Strooper B.

Mol Neurodegener. 2018 Oct 12;13(1):54. doi: 10.1186/s13024-018-0285-1.

34.

Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.

Abou-Khalil B, Klein P, Shah A, Ryvlin P, Specchio LM, Gama H, Rocha F, Blum D, Grinnell T, Cheng H, Jung J.

Epilepsy Res. 2018 Nov;147:80-86. doi: 10.1016/j.eplepsyres.2018.08.011. Epub 2018 Aug 29.

35.

Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator.

Chatterjee S, Cassel R, Schneider-Anthony A, Merienne K, Cosquer B, Tzeplaeff L, Halder Sinha S, Kumar M, Chaturbedy P, Eswaramoorthy M, Le Gras S, Keime C, Bousiges O, Dutar P, Petsophonsakul P, Rampon C, Cassel JC, Buée L, Blum D, Kundu TK, Boutillier AL.

EMBO Mol Med. 2018 Nov;10(11). pii: e8587. doi: 10.15252/emmm.201708587.

36.

Modifying the Impact of Eveningness Chronotype ("Night-Owls") in Youth: A Randomized Controlled Trial.

Harvey AG, Hein K, Dolsen MR, Dong L, Rabe-Hesketh S, Gumport NB, Kanady J, Wyatt JK, Hinshaw SP, Silk JS, Smith RL, Thompson MA, Zannone N, Blum DJ.

J Am Acad Child Adolesc Psychiatry. 2018 Oct;57(10):742-754. doi: 10.1016/j.jaac.2018.04.020. Epub 2018 Aug 15.

37.

The practice of dentistry in intensive care units in Brazil.

Blum DFC, Silva JASD, Baeder FM, Della Bona Á.

Rev Bras Ter Intensiva. 2018 Jul-Sept;30(3):327-332. doi: 10.5935/0103-507X.20180044. Epub 2018 Sep 3. Portuguese, English.

38.

Automatic Generation of Figural Analogies With the IMak Package.

Blum D, Holling H.

Front Psychol. 2018 Aug 6;9:1286. doi: 10.3389/fpsyg.2018.01286. eCollection 2018.

39.

The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease.

Cellai L, Carvalho K, Faivre E, Deleau A, Vieau D, Buée L, Blum D, Mériaux C, Gomez-Murcia V.

Front Neurosci. 2018 Aug 3;12:520. doi: 10.3389/fnins.2018.00520. eCollection 2018. Review.

40.

Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Faivre E, Coelho JE, Zornbach K, Malik E, Baqi Y, Schneider M, Cellai L, Carvalho K, Sebda S, Figeac M, Eddarkaoui S, Caillierez R, Chern Y, Heneka M, Sergeant N, Müller CE, Halle A, Buée L, Lopes LV, Blum D.

Front Mol Neurosci. 2018 Jul 12;11:235. doi: 10.3389/fnmol.2018.00235. eCollection 2018.

41.

The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Blum D, Chern Y, Domenici MR, Buée L, Lin CY, Rea W, Ferré S, Popoli P.

J Caffeine Adenosine Res. 2018 Jun 1;8(2):43-58. doi: 10.1089/caff.2018.0006. Review.

42.

Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease.

Blum D, la Fougère C, Pilotto A, Maetzler W, Berg D, Reimold M, Liepelt-Scarfone I.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2387-2395. doi: 10.1007/s00259-018-4085-1. Epub 2018 Jul 14.

PMID:
30008111
43.

Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors.

Temido-Ferreira M, Ferreira DG, Batalha VL, Marques-Morgado I, Coelho JE, Pereira P, Gomes R, Pinto A, Carvalho S, Canas PM, Cuvelier L, Buée-Scherrer V, Faivre E, Baqi Y, Müller CE, Pimentel J, Schiffmann SN, Buée L, Bader M, Outeiro TF, Blum D, Cunha RA, Marie H, Pousinha PA, Lopes LV.

Mol Psychiatry. 2018 Jun 27. doi: 10.1038/s41380-018-0110-9. [Epub ahead of print]

PMID:
29950682
44.

Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures.

Sunkaraneni S, Ludwig E, Fiedler-Kelly J, Hopkins S, Galluppi G, Blum D.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):649-658. doi: 10.1007/s10928-018-9596-7. Epub 2018 Jun 9.

45.

Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts.

Nguyen TD, Schwarzer M, Schrepper A, Amorim PA, Blum D, Hain C, Faerber G, Haendeler J, Altschmied J, Doenst T.

J Am Heart Assoc. 2018 Jun 21;7(13). pii: e008865. doi: 10.1161/JAHA.118.008865.

46.

Iatrogenesis Imperfecta Medicamentosa: Adverse Drug Events in Dialysis Patients are Associated with Higher Resource Utilization and Mortality.

Blum D, Chan CT.

Am J Nephrol. 2018;47(6):438-440. doi: 10.1159/000489704. Epub 2018 Jun 12. No abstract available.

47.

Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and β-Amyloid Peptide Load in Hypothyroid Rats.

Chaalal A, Poirier R, Blum D, Laroche S, Enderlin V.

Mol Neurobiol. 2019 Jan;56(1):722-735. doi: 10.1007/s12035-018-1111-z. Epub 2018 May 23.

PMID:
29796989
48.

Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate.

Gidal BE, Jacobson MP, Ben-Menachem E, Carreño M, Blum D, Soares-da-Silva P, Falcão A, Rocha F, Moreira J, Grinnell T, Ludwig E, Fiedler-Kelly J, Passarell J, Sunkaraneni S.

Acta Neurol Scand. 2018 Sep;138(3):203-211. doi: 10.1111/ane.12950. Epub 2018 May 6.

49.

Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?

Laurent C, Buée L, Blum D.

Biomed J. 2018 Feb;41(1):21-33. doi: 10.1016/j.bj.2018.01.003. Epub 2018 Mar 20. Review.

50.

Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.

Lee CC, Chang CP, Lin CJ, Lai HL, Kao YH, Cheng SJ, Chen HM, Liao YP, Faivre E, Buée L, Blum D, Fang JM, Chern Y.

Mol Neurobiol. 2018 Dec;55(12):8936-8952. doi: 10.1007/s12035-018-1030-z. Epub 2018 Apr 4.

PMID:
29616397

Supplemental Content

Support Center